Abstract
Stromal targeting with PDGFRα/β dual blockade reverses the immunosuppressive microenvironment and enhances the efficacy of immune checkpoint inhibitors in fibrotic cancer. See related commentary by Tauriello, p. 655.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have